Prevention of Sacituzumab Govitecan-related Neutropenia in Patients with metastatic Triple Nagative Breast Cancer who have received at least one, and no more than two, prior standard of care chemotherapy regimens
Signed Informed Consent Form (ICF) prior to participation in any study-related activities.
Patients aged ≥19 years at the time of signing ICF.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy of ≥ 12 weeks.
Prior treatment with topoisomerase 1 inhibitors as a free form or as other formulations.
Received any prior treatment with a Trop-2-directed ADC.
Patients with carcinomatous meningitis.
Known hypersensitivity reaction to any investigational or therapeutic compound or their incorporated substances.
Yeon Hee Park
Lead sponsor
Samsung Medical Center
Sponsor institution